Fei-Ting Hsu1, Yuan-Hao Lee2, Cheng-Shyong Chang3, Song-Shei Lin4, Yu-Chang Liu5,6,7, I-Tsang Chiang5,6,7, Jing-Gung Chung8, Jung-Hung Hsieh9, Chih-Hung Chiang9,10,11, Mao-Chi Weng12. 1. Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. sslin@ctust.edu.tw 1959johnchang@gmail.com YUAN-HAO.LEE@uth.tmc.edu sakiro920@mail.cmu.edu.tw. 2. Department of Ophthalmology and Visual Science, University of Texas Health Science Center at Houston, Houston, TX, U.S.A. sslin@ctust.edu.tw 1959johnchang@gmail.com YUAN-HAO.LEE@uth.tmc.edu sakiro920@mail.cmu.edu.tw. 3. Division of Hematology-Oncology, Department of Internal Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. sslin@ctust.edu.tw 1959johnchang@gmail.com YUAN-HAO.LEE@uth.tmc.edu sakiro920@mail.cmu.edu.tw. 4. Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. sslin@ctust.edu.tw 1959johnchang@gmail.com YUAN-HAO.LEE@uth.tmc.edu sakiro920@mail.cmu.edu.tw. 5. Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. 6. Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. 7. Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. 8. Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. 9. Department of Urology, Medical Research and Education, Taipei Veterans General Hospital, Yuan-Shan/Su-Ao Branch, Yilan, Taiwan, R.O.C. 10. Department of Nursing, Cardinal Tien Junior College of Healthcare and Management, New Taipei, Taiwan, R.O.C. 11. Department of Urology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. 12. Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan, R.O.C.
Abstract
BACKGROUND: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-κB) and compromise patients' survival. Regorafenib suppresses NF-κB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. MATERIALS AND METHODS: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. RESULTS: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-κB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. CONCLUSION: Regorafenib may enhance the anti-CRC efficacy of RT. Copyright
BACKGROUND: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-κB) and compromise patients' survival. Regorafenib suppresses NF-κB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. MATERIALS AND METHODS: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. RESULTS: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-κB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. CONCLUSION:Regorafenib may enhance the anti-CRC efficacy of RT. Copyright
Authors: Lucrezia Manente; Stefano Pecoraro; Esther Picillo; Umberto Gargiulo; Paolo Gargiulo; Antonio De Luca; Luisa Politano Journal: In Vivo Date: 2015 Mar-Apr Impact factor: 2.155
Authors: Santosh K Sandur; Amit Deorukhkar; Manoj K Pandey; Ana María Pabón; Shujun Shentu; Sushovan Guha; Bharat B Aggarwal; Sunil Krishnan Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-01 Impact factor: 7.038